Assertio Therapeutics (NASDAQ:ASRT) reported Q2 EPS of $0.28, $0.20 better than the analyst estimate of $0.08. Revenue for the quarter came in at $35.4 million versus the consensus estimate of $31.63 million.
Assertio Therapeutics (NASDAQ:ASRT) reported Q2 EPS of $0.28, $0.20 better than the analyst estimate of $0.08. Revenue for the quarter came in at $35.4 million versus the consensus estimate of $31.63 million.